Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Metabo3DC

Financiado

Understanding Metabolic Activation of Dendritic Cells in Non-Alcoholic Fatty Liv...

Understanding Metabolic Activation of Dendritic Cells in Non-Alcoholic Fatty Liver Disease Non-alcoholic fatty liver disease (NAFLD) is a major global health problem with no approved treatments, and dire outcomes for patients. The pathogenesis of NAFLD is clearly linked to metabolic alterations, and is primarily charact... ver más

31/08/2027

INSERM

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-04-19

ERC-2021-STG: ERC STARTING GRANTS Scope:Objectives

I+D

Cerrada hace 3 años

0% 100% 100%

2 Participantes

INSERM

2.41M€ | Lider

UNIVERSITE DE LILLE

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

LIPIDEMIA Initiation Mechanisms of Lipid-driven Diseases 207K€ Cerrado

PID2020-114710RB-I00 DESENTRAÑANDO LA HETEROGENEIDAD DE LA ENFERMEDAD DEL HIGADO... 290K€ Cerrado

ForgettingNAFLD Unravelling the pathogenic cell-cell circuits underlying the... 176K€ Cerrado

SAF2014-52097-R PAPEL DE LA S-ADENOSILMETIONINA (SAME) EN LA PATOGENESIS Y T... 303K€ Cerrado

MacTalk Adipose tissue-Liver Macrophage CrossTalk in NASH and Fibros... 203K€ Cerrado

PID2020-115055RB-I00 INTERACCION DE LAS PROTEINAS MITOCONDRIALES STARD1 Y SAB EN... 218K€ Cerrado

Duración del proyecto: 64 meses Fecha Inicio: 2022-04-19
Fecha Fin: 2027-08-31

Líder del proyecto

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Descripción del proyecto Non-alcoholic fatty liver disease (NAFLD) is a major global health problem with no approved treatments, and dire outcomes for patients. The pathogenesis of NAFLD is clearly linked to metabolic alterations, and is primarily characterized by excessive hepatic triglyceride content. Over time, metabolic dysfunction induces hepatic inflammation through mechanisms that remain poorly understood. This advanced disease stage, called non-alcoholic steatohepatitis (NASH), significantly raises the risk of hepatocellular carcinoma, cardiovascular disease and type-2 diabetes. My recent work has helped demonstrate that: 1) changes in conventional dendritic cell (cDC) populations in liver are closely associated with the development and the resolution of NASH in humans, and 2) extracellular metabolites can modulate cDC cytokine production and responses by rewiring their intracellular metabolic programs. Together, these studies indicate that alterations of the local hepatic metabolite environment could affect cDC function and thereby drive NASH pathogenesis. cDCs coordinate innate and adaptative immunity through cytokine secretion and antigen presentation. However, their role in NAFLD pathophysiology not well defined. In this ambitious multidisciplinary project, my objective is to systematically dissect the immuno-metabolic programs and functions of hepatic cDC during NASH progression and regression. First, we will identify disease-associated cDC subpopulations and their intracellular metabolic programs. We will then determine whether these cDC subtypes associate with specific local metabolic microenvironments in the liver in relation to histological features of NAFLD. Finally, we will determine how metabolic manipulation of cDC affects their immune function in the context of NASH. The present proposal has the potential to radically transform our understanding of NASH pathophysiology by delineating the specific links between metabolic dysfunction and innate immunity in liver disease.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores